Premium
The new antidepressant zimeldine in general practice. A surveillance study of 15,000 patients
Author(s) -
Fünfgeld E. W.
Publication year - 1983
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1983.tb11108.x
Subject(s) - antidepressant , reuptake inhibitor , medicine , drug , psychology , psychiatry , anxiety
— The safety and efficacy of zimeldine – the 5‐HT reuptake blocker – was investigated in a 3‐week open surveillance study of 15,000 out‐patients with depressive illness. In general, a single daily dose of 200 mg of zimeldine was given to adults for a minimum of 3 weeks. Patients of 65 years or over received 100 mg. The drug was well tolerated and troublesome side‐effects occurred in only a small percentage of patients. No previously unencountered side‐effects or new pattern of side‐effects emerged from this study. The general impression of the efficacy of zimeldine confirmed previous findings (i.e. that zimeldine is an effective antidepressant).